the present invention will now be described more specifically with reference to the following embodiments . it is to be noted that the following descriptions of preferred embodiments of this invention are presented herein for purpose of illustration and description only ; it is not intended to be exhaustive or to be limited to the precise form disclosed . optical rotations were taken on a jasco - p - 1020 polarimeter ( cell length 10 mm ). uv spectra were measured on a jasco v - 530 uv / vis spectrophotometer . infrared resonance ( ir ) spectra were recorded on a mattson genesis ii ft - ir spectrophotometer . nuclear magnetic resonance ( nmr ) spectra were recorded on varian gemini - 20000 ( 200 mhz ), varian unity - plus ( 400 mhz ), and varian unity - plus ( 600 mhz ) ft - nmr . nmr spectrometers . chemical shift ( δ ) values are in ppm ( part per million ) with deuterated chloroform ( cdcl 3 ) as internal standard , and coupling constants ( j ) are in hz . high resolution fast atom bombardment mass spectrum ( hrfabms ), high resolution electrospray ionization mass spectrometry ( hresims ), and electrospray ionization mass spectrometry ( esims ) measurements respectively were performed on jeol jms - 700 , bruker apex ii , and finnigan polarisq mass spectrometers . thin layer chromatography ( tlc ) was performed on kieselgel 60 f 254 ( 0 . 20 mm , merck ), and spots were viewed under uv light at 254 nm and 356 nm and / or stained by spraying with 50 % h 2 so 4 and heating on a hot plate . for column chromatography , silica gel ( kieselgel 60 , 70 - 230 , and 230 - 400 mesh , merck ) and sephadex lh - 20 were used . the instrumentation for the reverse phase - medium performance liquid chromatography ( rp - mplc ) experiment was composed of a supelco versaflash flash chromatography apparatus and versaflash c - 18 cartridges ( 40 × 150 mm ). further purification of some of compounds obtained was achieved by preparative high performance liquid chromatography ( hplc ), using a shimadzu lc - 10atvp / shimadzu scl - 10avp uv - vis detector and thermo columns ( analytical : 5 μm , 250 × 4 . 6 mm ; preparative : 8 μm , 250 × 10 mm ; c 18 ) were used . for the preparation of mosher ester derivatives , ( s )-(+)- and ( r )-(−)- α - methoxy - α -( trifluoromethyl )- phenylacetyl chloride were used as the reagents . ferula assa - foetida resin ( 3 . 23 kg ) was purchased from a chinese herb shop in taipei , taiwan . please refer to fig1 , which depicts the flowchart of the fractions extracted from f . assa - foetida . in the method 10 , f . assa - foetida resin ( 3 . 23 kg ) was extracted four times with methanol ( meoh , 5 l each ) at room temperature ( step 11 ) to obtain a crude extract ( 313 . 8 g , step 12 ). the crude extract was partitioned between n - hexane - methanol ( 1 : 1 ), and then the methanol extract ( 120 . 1 g , step 13 ) was partitioned between chloroform ( chcl 3 )— h 2 o ( 1 : 1 ), to obtain a chloroform extract ( 65 . 2 g , step 14 ), which showed significant anti - h 1 n 1 antiviral and cytotoxic activities ( referring to the experimental results as follows ). initial fractionation of the chloroform extract ( 65 . 2 g ) was carried out by open column chromatography on silica gel ( 230 - 400 mesh , column : 7 × 30 cm ), using gradients of n - hexane - chcl 3 - methanol ( 100 : 0 : 0 to 0 : 80 : 20 ), and gave 11 fractions ( step 15 ). a precipitation was obtained from the first chromatographic step , using n - hexane as the eluent , and was washed with a trace amount of n - hexane to afford oleic acid ( 2 . 0 g ). please refer to fig2 , which depicts the further extraction flowchart of fraction 3 in the present invention . in the method 20 , fraction 3 ( 6 . 66 g , step 21 ) was fractionated into 15 fractions by silica gel chromatography ( 70 - 230 mesh , column : 5 × 23 cm ; chcl 3 ) ( step 22 ). subfraction 3 - 6 ( 602 . 06 mg , step 23 ) was subjected to silica chromatography ( 70 - 230 mesh , column : 3 × 20 cm ; n - hexane - ethyl acetate ( etoac ), 1 : 1 ) and purified by preparative tlc ( chcl 3 ) to give compound 9 ( 1 . 9 mg , step 24 ). subfraction 3 - 7 ( 619 . 90 mg , step 25 ) was purified by solid - phase extraction ( spe ) ( dsc - 18 , 60 ml , 10gms , no . 52609 - u ; meoh — h 2 o , 80 : 20 ) to obtain vanillin ( 23 . 5 mg , step 26 ). please refer to fig3 , which depicts the further extraction flowchart of fraction 4 in the present invention . in the method 30 , fraction 4 ( 11 . 78 g , step 31 ) was separated into 8 subfractions ( step 32 ) by column chromatography on silica gel ( 70 - 230 mesh , column : 7 × 24 cm ; n - hexane - etoac , 1 : 1 ) and crystalline β - sitosterol ( 0 . 30 g ) was obtained with meoh . subfraction 4 - 6 ( step 33 ) was subjected to silica gel chromatography ( 70 - 230 mesh , column : 5 × 17 cm ; chcl 3 - meoh , 60 : 1 ) to give 6 subfrations ( step 34 ). subfraction 4 - 6 - 2 ( step 35 ) was purified with hplc ( ods thermo ®, 10 × 250 mm ; meoh — h 2 o , 78 : 22 ; flow rate : 3 . 0 ml / min ) to give lehmannolone ( 1 . 7 mg , t r = 31 min , step 36 ). subfraction 4 - 6 - 4 ( step 37 ) was purified by preparative tlc ( chcl 3 ) to give compound 4 ( 5 . 7 mg ) and lehmferin ( 2 . 8 mg , step 38 ). subfraction 4 - 6 - 5 ( 400 mg , step 39 ) was chromatographed on a silica gel column ( 70 - 230 mesh , column : 2 . 5 × 28 cm ), using n - hexane - dichloromethane ( ch 2 cl 2 ) ( 2 : 7 ) as eluent , and subfraction 4 - 6 - 5 - 1 ( 253 . 30 mg , step 40 ) was purified subsequently with n - hexane - etoac ( 7 : 2 ), to obtain 7 subfractions ( step 41 ). subfractions 4 - 6 - 5 - 1 - 2 ( 9 . 5 mg , step 42 ), 4 - 6 - 5 - 1 - 3 ( 68 . 7 mg , step 44 ), and 4 - 6 - 5 - 1 - 6 ( 21 . 9 mg , step 46 ) were purified by rp - hplc ( flow rate : 3 . 0 ml / min ) to give fetidone b ( 2 . 2 mg , meoh — h 2 o 70 : 30 , t r = 14 min ), a farnesiferol b and assafoetidin mixture ( 16 . 4 mg , meoh — h 2 o 63 : 37 , t r = 123 min ) ( step 43 ), feselol ( 3 . 3 mg , meoh — h 2 o 63 : 37 , t r = 136 min , step 45 ), and compound 1 ( 2 . 3 mg , meoh — h 2 o 70 : 30 , t r = 34 min , step 47 ), respectively . subfractions 4 - 6 - 5 - 2 ( 43 . 4 mg , step 48 ) and 4 - 6 - 7 ( 354 . 7 mg , step 50 ) were purified by rp - hplc ( meoh — h 2 o 76 : 24 ; flow rate : 3 . 0 ml / min ) to give ( i ) compounds 10 ( 8 . 9 mg , t r = 38 min ) and 11 ( 6 . 2 mg , t r = 41 min ) ( step 49 ), and ( ii ) compounds 7 ( 58 . 9 mg , t r = 27 min ), 8 ( 15 . 7 mg , t r = 31 min ) and 7 - oxocallitrisic acid ( 1 . 5 mg , t r = 53 min ) ( step 51 ), respectively . subfraction 4 - 7 ( 12 . 40 g , step 52 ) was separated by silica gel chromatography ( 70 - 230 mesh , column : 5 × 25 cm ; chcl 3 - meoh , 60 : 1 ) into 6 subfractions ( step 53 ). subfraction 4 - 7 - 4 ( 746 . 80 mg , step 54 ) was subjected to silica gel chromatography ( 70 - 230 mesh , column : 3 × 20 cm ; n - hexane - etoac , 5 : 2 ) and purified by rp - hplc ( meoh — h 2 o , 75 : 25 ; flow rate : 3 . 0 ml / min ) to give compounds 2 ( 19 . 7 mg , t r = 24 min ), 6 ( 57 . 0 mg , t r = 34 min ) and 13 ( 11 . 6 mg , t r = 12 min ) ( step 55 ). the chcl 3 / meoh - insoluble umbelliferone ( 3 . 4 mg , step 58 ) was obtained from subfraction 4 - 8 - 7 ( 58 . 2 mg , step 57 ). please refer to fig4 , which depicts the further extraction flowchart of fraction 5 in the present invention . in the method 40 , fraction 5 ( 11 . 77 g , step 61 ) was chromatographed over silica gel ( 70 - 230 mesh , column : 5 × 30 cm ; chcl 3 - meoh , 50 : 1 ), with subfraction 5 - 2 ( 334 . 30 mg , step 62 ) then subjected to rp - mplc ( meoh — h 2 o , 65 : 35 ), to give 5 subfractions ( step 63 ). subfraction 5 - 2 - 1 ( step 64 ) was purified by rp - hplc ( meoh — h 2 o , 61 : 39 ; flow rate : 3 . 0 ml / min ) to give foetisulfide a ( 1 . 5 mg , t r = 43 min , step 65 ). subfraction 5 - 3 ( 255 . 2 mg , step 66 ) was subjected to rp - mplc ( meoh — h 2 o , 70 : 30 ) and subfraction 5 - 3 - 3 ( 112 . 3 mg , step 67 ) was purified by silica gel chromatography ( 70 - 230 mesh , column : 2 . 5 × 30 cm ; ch 2 cl 2 - meoh , 40 : 1 ) to obtain kamolonol ( 14 . 3 mg , step 68 ). subfraction 5 - 3 - 4 ( 351 . 4 mg , step 69 ) was chromatographed by rp - hplc ( meoh — h 2 o , 65 : 35 ; flow rate : 3 . 0 ml / min ) to give microlobin ( 30 . 4 mg , t r = 73 min , step 70 ) and then the mother liquor was purified by rp - hplc ( meoh — h 2 o , 53 : 47 ; flow rate : 3 . 0 ml / min ) to give compound 12 ( 21 . 3 mg , t r = 64 min ) and foetisulfide c ( 3 . 6 mg , t r = 50 min ) ( step 72 ). subfractions 5 - 3 - 5 ( step 73 ) and 5 - 3 - 6 ( step 75 ) were chromatographed over silica gel ( 70 - 230 mesh , column : 1 . 5 × 25 cm ; ch 2 cl 2 - meoh , 60 : 1 and 50 : 1 ) to give picealactone c ( 0 . 7 mg , step 74 ) and compound 5 ( 241 . 7 mg , step 76 ). subfraction 5 - 5 ( 352 . 3 mg , step 77 ) was chromatographed by rp - hplc ( meoh — h 2 o , 72 : 28 ; flow rate : 3 . 0 ml / min ) to give compound 3 ( 7 . 0 mg , t r = 16 min , step 78 ). please refer to fig5 , which depicts the further extraction flowchart of fraction 6 in the present invention . in the method 50 , fraction 6 ( 4 . 33 g , step 81 ) was chromatographed over silica gel ( 70 - 230 mesh , column : 7 × 35 cm ; ch 2 cl 2 - meoh , 25 : 1 ) to give 5 subfractions ( step 82 ). subfraction 6 - 3 ( step 83 ) was purified with rp - mplc ( meoh — h 2 o , 55 : 45 ) to give polyanthinin ( 23 . 4 mg , step 84 ). the chemical formulas , physical and chemical properties of brand new compounds 1 ( formula i ), 2 ( formula ii ) and 3 ( formula iii ) in the present invention are illustrated as follows . physical and chemical properties : yellow oil ; [ α ] 25 d + 8 . 6 ( c 0 . 12 , chcl 3 ); uv ( meoh ) λ max ( log ε ) 211 ( 4 . 54 ), 318 ( 3 . 95 ) nm ; ir ( neat ) ν max 3440 , 1729 , 1613 , 1555 , 1233 , 836 cm − 1 ; 1 h and 13 c nmr ( cdcl 3 , 400 mhz ), see table 1 ; esims m / z 463 [ m + na ] + ; hresims m / z 463 . 2099 [ m + na ] + ( calcd for c 26 h 32 o 6 na , 463 . 2096 ). physical and chemical properties : yellow oil ; [ α ] 25 d + 11 . 2 ( c 0 . 5 , chcl 3 ); uv ( meoh ) λ max ( log ε ) 213 ( 4 . 77 ), 321 ( 4 . 39 ) nm ; ir ( neat ) ν max 3480 , 1731 , 1613 , 1555 , 1234 , 836 cm − 1 ; 1 h and 13 c nmr ( cdcl 3 , 400 mhz ), see table 1 ; esims m / z 465 [ m + na ] + ; hrfabms m / z 443 . 2433 [ m + h ] + ( calcd for c 26 h 34 o 6 + h , 443 . 2434 ). physical and chemical properties : yellow oil ; [ α ] 25 d − 14 . 6 ( c 0 . 16 , chcl 3 ); uv ( meoh ) λmax ( log ε ) 243 ( 3 . 95 ), 271 ( 3 . 74 ) nm ; ir ( neat ) ν max 3417 , 1696 , 1613 , 1514 cm − 1 ; 1 h and 13 c nmr ( cdcl 3 , 400 mhz ), see table 2 ; esims m / z 337 [ m + na ] + ; hresims m / z 337 . 1784 [ m + na ] + ( calcd for c 20 h 26 o 3 na , 337 . 1780 ). madin - darby canine kidney ( mdck ) cells ( atcc ccl34 ) were used as target cells for viral infection in the xtt ( tetrazolium hydroxide salt ) assay . mdck cells were grown as adherent cells in mem medium supplemented with 10 % fetal calf serum ( fcs ), 100 u / ml penicillin g , 100 μg / ml streptomycin , and 0 . 25 μg / ml amphotericin b . in the antiviral assay , the medium was supplemented with 2 % fcs and the above - mentioned antibiotics . virus titers were determined by the cytopathic effect in mdck cells and expressed as 50 % tissue culture infective dose ( tcid 50 ) values per ml . all viruses were stored at − 70 ° c . until use . the antiviral activity against influenza a virus ( h 1 n 1 ) was evaluated by the xtt method . mdck cells , treated by trypsin , were seeded onto 96 - well plates with a concentration of 1 . 0 × 10 5 cells / ml and a volume of 70 μl per well . after incubation at 35 ° c . with 5 % co 2 for 24 hours , 20 μl of test virus solution were added and incubated for another 1 hour . different concentrations of test substances were then added to culture wells in triplicate . amantadine was used as a positive control . after incubation at 35 ° c . with 5 % co 2 for 3 days , xtt reagent was added and incubated for 3 hours . the viral inhibition rate (%) was calculated as [ 100 −( od 492 / od 690 )× 100 ]%. the antiviral concentration of 50 % inhibition ( ic 50 ) was defined as the concentration achieving 50 % cytoprotection against virus infection . fractions and isolates were tested against lung ( a549 ), breast ( mea - mb - 231 and mcf7 ), liver ( hepg2 and hep3b ), and oral ( ca9 - 22 ) human cancer cell lines using an established colorimetric mtt ( diphenyltetrazolium bromide ) assay protocol . doxorubicin was used as a positive control . in brief , freshly trypsinized cancer cell suspensions were seeded in 96 - well microtiter plates at densities of 5 , 000 - 10 , 000 cells per well with test compounds added from a dimethyl sulfoxide ( dmso ) stock solution . after 3 days in culture , the attached cells were incubated with mtt ( 0 . 5 mg / ml , 1 hour ) and subsequently solubilized in dmso . the absorbance was measured at 550 nm using an elisa reader . the ic 50 is the concentration of agent that reduced cell growth by 50 %, under the experimental conditions used . for conveniently illustrating compounds 1 to 13 extracted in the present invention , the structural formulas ( i to xiii ) corresponding to compounds 1 to 13 are listed as follows . a meoh extract of the resin of f . assa - foetida was partitioned between n - hexane - meoh ( 1 : 1 ) and then the meoh layer was partitioned between chcl 3 - h 2 o ( 1 : 1 ) to obtain a chcl 3 extract , which showed significant anti - h 1 n 1 activity ( ic 50 & lt ; 3 . 4 μg / ml ) and cytotoxicity for lung , breast and oral human cancer cell lines ( ic 50 & lt ; 20 μg / ml ). initial fractionation of the chcl 3 extract was carried out by open liquid chromatography on silica gel to give 11 fractions . chromatographic fractionation of these active subfractions provided two new sesquiterpene coumarins ( compounds 1 and 2 ), a new diterpene ( compound 3 ), and 27 known compounds . hresims of compound 1 exhibited a [ m + na ] + ion at m / z 463 . 2099 ( c 26 h 32 o 6 na ). the ir spectrum showed absorptions for hydroxy ( 3440 cm − 1 ), acetoxy ( 1729 cm − 1 ), and aromatic ( 1613 and 1555 cm − 1 ) functional groups . uv absorptions at 211 and 318 nm also indicated a coumarin nucleus oxygenated at the c - 7 position . in the 13 c nmr spectrum , compound 1 displayed 26 carbon signals , with nine being typical for an umbelliferone skeleton [( δ 101 . 5 ( c - 8 ), 112 . 5 ( c - 10 ), 113 . 1 ( c - 3 ), 114 . 2 ( c - 6 ), 128 . 7 ( c - 5 ), 143 . 4 ( c - 4 ), 155 . 8 ( c - 9 ), 161 . 2 ( c - 2 ), and 161 . 9 ( c - 7 )] and the remaining 17 signals ascribable to a sesquiterpene moiety [ δ 18 . 0 ( c - 13 ′), 13 . 1 ( c - 14 ′), 17 . 1 ( c - 15 ′), 25 . 9 ( c - 12 ′), 34 . 2 ( c - 9 ′), 44 . 9 ( c - 4 ′), 65 . 2 ( c - 1 ′), 68 . 9 ( c - 5 ′), 75 . 9 ( c - 8 ′), 119 . 5 ( c - 10 ′), 122 . 1 ( c - 2 ′), 123 . 3 ( c - 6 ′), 135 . 5 ( c - 11 ′), 137 . 6 ( c - 3 ′), 141 . 9 ( c - 7 ′)] with an acetoxy group ( δ 21 . 2 and 170 . 3 ). in the 1 h nmr spectrum , signals for two main moieties , a coumarin and a sesquiterpene , were revealed . the coumarin moiety appeared as 5 signals [ δ h 6 . 24 and 7 . 63 ( each 1h , d , j = 9 . 4 hz ), 7 . 35 ( 1h , d , j = 8 . 4 hz ), 6 . 82 ( 1h , dd , j = 2 . 4 , 8 . 4 hz ), 6 . 79 ( 1h , d , j = 2 . 4 hz )]. in turn , the sesquiterpene moiety displayed signals for 4 methyls [ δ h 1 . 62 , ( 3h , brs ), 1 . 71 ( 3h , brs ), 1 . 72 ( 3h , brs ), 1 . 81 , ( 3h , s )], 2 methylenes [ δ h 2 . 23 ( 2h , m ), 2 . 28 ( 1h , d , j = 6 . 0 hz ), 2 . 45 ( 1h , dd , j = 7 . 6 , 13 . 6 hz )], an oxygenated methylene [ δ h 4 . 57 ( 2h , d , j = 6 . 2 hz )], 3 olefinic methines [ δ h 5 . 08 ( 1h , brt , j = 6 . 4 hz ), 5 . 41 ( 1h , d , j = 8 . 8 hz ), 5 . 50 ( 1h , brt , j = 6 . 2 hz )], and 2 oxygenated methines [ δ h 3 . 99 ( 1h , brt , j = 6 . 4 hz ), 5 . 70 ( 1h , m )]. compound 1 gave the same molecular formula , c 26 h 32 o 6 , and similar 1d nmr data to compound 6 ( 8 ′- acetoxy - 5 ′- hydroxyumbelliprenin ) with the only difference being due to the placement of an acetoxy group and a hydroxy group . the key heteronuclear multiple bond correlation ( hmbc ) correlations suggested that the acetoxy and hydroxy groups could be positioned at c - 5 ′ and c - 8 ′, respectively ( fig6 ). the hmbc correlation of an oxygenated methylene δ h 4 . 57 ( h - 1 ′) with a carbon signal at δ c 161 . 9 ( c - 7 ) indicated that the sesquiterpene unit is attached to c - 7 of the coumarin moiety via an ether linkage . the new compound 1 was therefore assigned as 5 ′- acetoxy - 8 ′- hydroxyumbelliprenin . a [ m + h ] + ion at m / z 443 . 2433 ( c 26 h 35 o 6 ) was present in the hrfabms of compound 2 . ir spectrum showed absorptions for hydroxy ( 3480 cm − 1 ), acetoxy ( 1731 cm − 1 ), and aromatic ( 1613 and 1555 cm − 1 ) functional groups . uv absorptions at 213 and 321 nm indicated a coumarin nucleus oxygenated at the c - 7 position . in the 1d nmr spectrum ( table 1 ), the signals indicated a carbon skeleton with two main moieties , a coumarin and a sesquiterpene . on the basis of hmbc correlations [ δ h 4 . 59 ( h - 1 ′)/ δ c 162 . 1 ( c - 7 ), 118 . 4 ( c - 2 ′), and 142 . 2 ( c - 3 ′); δ h 4 . 77 ( h - 10 ′)/ δ c 171 . 2 ( o c och 3 ); δ h 1 . 17 ( h - 12 ′)/ δ c 79 . 5 ( c - 10 ′), 72 . 4 ( c - 11 ′), and 26 . 7 ( c - 13 ′); δ h 1 . 18 ( h - 13 ′)/ δ c 79 . 5 ( c - 10 ′), 72 . 4 ( c - 11 ′), and 24 . 8 ( c - 12 ′)], the sesquiterpene unit could be attached to c - 7 ( δ 162 . 1 ) of the coumarin moiety via an ether linkage , and the acetoxy and hydroxy groups were positioned at c - 10 ′ ( δ 79 . 5 ) and c - 11 ′ ( δ 72 . 4 ), respectively . compound 2 was elucidated as 10 ′- acetoxy - 11 ′- hydroxyumbelliprenin . to determine the only chiral center at c - 10 ′, compounds 2 and 5 ( 10 ′- karatavicinol ) possess the same biogenetic origin is speculated . compound 5 was treated separately with ( r )- and ( s )- α - methoxy - α -( trifluoromethyl )- phenylacetyl chloride [( r )- and ( s )- mtpa - cl ] in the presence of c 5 d 5 n , to yield the ( s )- and ( r )- mtpa esters ( fig8 ), respectively . the mtpa esters were generated successfully at c - 10 ′ as elucidated from the 1 h nmr spectra ( compound 5a , h - 8 ′ δ 2 . 15 , h - 9 ′ δ 2 . 15 , h - 10 ′ δ 5 . 49 , h - 12 ′ δ 1 . 37 , h - 13 ′ δ 1 . 70 ; compound 5b , h - 8 ′ δ 2 . 13 , h - 9 ′ δ 2 . 13 , h - 10 ′ δ 5 . 50 , h - 12 ′ δ 1 . 43 , h - 13 ′ δ 1 . 71 ). the differences between the 1 h nmr chemical shifts for 5a and 5b ( δ values shown in fig8 ) led to the assignment of the r - configuration at c - 10 ′ of compound 5 . from a comparison of the specific rotation data of compounds 5 ([ α ] 25 d + 16 . 2 ) and 2 ([ α ] 25 d + 11 . 2 ), the absolute configuration of compound 2 at c - 10 ′ could therefore be assigned with a r configuration . compound 2 was established as 10 ′ r - acetoxy - 11 ′- hydroxyumbelliprenin . compound 3 gave the molecular formula , c 20 h 26 o 3 , as determined by hresims ( m / z 337 . 1784 [ m + na ] + ), indicating 8 degrees of unsaturation . its ir spectrum showed absorptions attributable to hydroxy ( 3417 cm − 1 ), carboxylic acid ( 1696 cm − 1 ), and aromatic ring ( 1613 and 1514 cm − 1 ) functions . based on its 13 c nmr and dept ( distortionless enhancement by polarization transfer data ), compound 3 showed 20 carbon signals , including 4 methyls ( δ c 17 . 7 , 20 . 7 , 31 . 6 , 31 . 6 ), 3 methylenes ( δ c 18 . 3 , 35 . 2 , 35 . 6 ), 6 methines ( δ c 46 . 3 , 121 . 6 , 122 . 8 , 123 . 7 , 128 . 3 , 130 . 0 ), and 7 quaternary ( δ c 37 . 1 , 46 . 0 , 72 . 4 , 132 . 4 , 145 . 9 , 146 . 6 , 183 . 5 ) carbons ( table 2 ). among the seven quaternary carbons , one was assigned as a carbonyl carbon at δ 183 . 5 . therefore , the data supported the presence of one carbonyl , 4 olefins , and 3 ring moieties to fulfill the 8 degrees of unsaturation apparently , and compound 3 was postulated to be an abietane - type diterpene . the hmbc correlations [ δ h 1 . 57 ( h - 16 )/ δ c 72 . 4 ( c - 15 ), 31 . 6 ( c - 17 ), and 146 . 6 ( c - 13 ); δ h 1 . 57 ( h - 17 )/ δ c 72 . 4 ( c - 15 ), 31 . 6 ( c - 16 ), and 146 . 6 ( c - 13 ); δ h 1 . 40 ( h - 19 )/ δ c 35 . 6 ( c - 3 ), 46 . 0 ( c - 4 ), 46 . 3 ( c - 5 ), and 183 . 5 ( c - 18 )] suggested the hydroxy and carboxylic groups to be located at c - 15 ( δ 72 . 4 ) and c - 4 ( δ 46 . 0 ), respectively ( fig7 ). the noesy ( nuclear overhauser effect spectroscopy ) correlation between me - 19 and me - 20 as well as the absence of noesy correlations between h - 5 / me - 19 and h - 5 / me - 20 indicated β and α orientations , respectively , for me - 20 and h - 5 ( trans a / b ring junction ). compound 3 was therefore elucidated as 15 - hydroxy - 6 - en - dehydroabietic acid . this is the first diterpene with an abietane skeleton from the genus ferula . the absolute configuration of compound 6 ( 8 ′- acetoxy - 5 ′- hydroxyumbelliprenin ) at c - 5 ′ was still unknown at the time of the present invention . compound 6 was treated separately with ( r )- and ( s )- mtpa - cl in c 5 d 5 n to yield the ( s )- and ( r )- mtpa esters ( compounds 6a and 6b , referring to fig8 ), respectively . the mtpa esters were generated successfully at c - 5 ′ as elucidated from the 1 h nmr spectra ( compound 6a : h - 2 ′ δ 5 . 58 , h - 4 ′ a δ 2 . 37 , h - 4 ′ b δ 2 . 31 , h - 5 ′ δ 6 . 20 , h - 6 ′ δ 5 . 70 , h - 8 ′ δ 5 . 35 , h - 14 ′ δ 1 . 93 , h - 15 ′ δ 1 . 72 ; compound 6b : h - 2 ′ δ 5 . 69 , h - 4 ′ a δ 2 . 41 , h - 4 ′ b δ 2 . 35 , h - 5 ′ δ 6 . 13 , h - 6 ′ δ 5 . 49 , h - 8 ′ δ 5 . 30 , h - 14 ′ δ 1 . 79 , h - 15 ′ δ 1 . 94 ). the differences between the 1 h nmr chemical shifts for compounds 6a and 6b ( δ values shown in fig8 ) led to the assignment of the s - configuration at c - 5 ′, and compound 6 was determined as 8 ′- acetoxy - 5 ′ s - hydroxyumbelliprenin . as to other compounds 4 , 7 to 13 extracted from f . assa - foetida in the present invention , according to the literatures , they are assigned as 5 ′- hydroxyumbelliprenin ( formula iv , appendino et al ., 1994 ), methyl galbanate ( formula vii , appendino et al ., 1994 ; yang et al ., 2006 ), galbanic acid ( formula viii , yang et al ., 2006 ), farnesiferol c ( formula ix , abd el - razek et al ., 2007 ; yang et al ., 2006 ), farnesiferol a ( formula x , abd el - razek et al ., 2007 ), conferol ( formula xi , zhou et al ., 2000 ), ligupersin a ( formula xii , iranshahi et al ., 2009 ), epi - conferdione ( formula xiii , abd el - razek et al ., 2007 ). 4 . anti - h 1 n 1 virus activity and anti - cancer activity of sesquiterpene coumarin regarding the in vitro anti - influenza a ( h 1 n 1 ) virus assay , the test drugs are the pure 7 - o - sesquiterpene coumarins , including compounds 2 and 4 to 13 , with amantadine as the positive control . the results are shown in table 3 . in table 3 , most of these compounds exhibited a higher antiviral potency than amantadine , except for compounds 2 , 5 and 12 . because the structures of many these compounds are quite similar , the results in table 3 are further discussed as follows . for example , compound 6 ( oh - 5 , oac - 8 ′) has an additional acetoxy group in comparison with compound 4 ( oh - 5 ′), but compound 6 was much less potent than compound 4 . compound 2 ( oac - 10 ′) has the same skeleton as compound 5 ( oh - 10 ′), and these two compounds showed a similar potency to the positive control , amantadine . between compounds 7 ( cooch 3 - 3 ′) and 8 ( cooh - 3 ′), compound 7 showed better potency than compound 8 , and therefore indicated that methyl esterification of c - 3 ′ enhanced the activity in the bioassay used . for the bicyclic - sesquiterpene coumarins , compounds 12 and 13 , a c - 3 ′- carbonyl afforded greater potency than a c - 3 ′- oh in this kind of skeleton . overall , the present invention has determined that sesquiterpene coumarins from f . assa - foetida may serve as promising lead compounds for new drug development against influenza a ( h 1 n 1 ) viral infection . a standardized plant extract of f . assa - foetida , may also be worthy of being further investigated as a new phytomedicine . furthermore , please refer to table 4 , the compounds in the present invention were screened in a cytotoxicity assay on the cancer cells with doxorubicin as the positive control . compound 11 exhibited the best potency ( ic 50 0 . 51 , 2 . 6 , and 3 . 4 μg / ml ) against hepg2 , hep3b , and mcf - 7 tested cancer cell lines , respectively . in addition , compound 11 also showed high potency influenza activity ( ic 50 0 . 47 ± 0 . 05 μg / ml ). the remaining compounds were all inactive for all cancer cell lines ( ic 50 & gt ; 4 μg / ml ). accordingly , the chloroform extract extracted from f . assa - foetida and the further extracted and chromatographed compounds in the present invention can effectively inhibits influenza a ( h 1 n 1 ) virus , and have cytotoxicity on human cancer cell lines . while the invention has been described in terms of what is presently considered to be the most practical and preferred embodiments , it is to be understood that the invention needs not be limited to the disclosed embodiments . on the contrary , it is intended to cover various modifications and similar arrangements included within the spirit and scope of the appended claims , which are to be accorded with the broadest interpretation so as to encompass all such modifications and similar structures .
new pharmaceutical compositions extracted from ferula assa - foetida are confirmed to effectively treat influenza a virus . the extraction method of the new pharmaceutical compositions mainly includes steps of extracting f . assa - foetida with methanol to obtain a crude extract ; fractioning the crude extract with n - hexane - methanol to obtain a methanol extract ; fractioning the methanol extract with chloroform - water to obtain a chloroform extract ; and chromatographing the chloroform extract to obtain the pharmaceutical compositions , which can be further fractioned and chromatographed to obtain various sesquiterpene coumarins .